Skip to main content
Erschienen in: CNS Drugs 10/2010

01.10.2010 | Review Article

Flupirtine in Pain Management

Pharmacological Properties and Clinical Use

verfasst von: Prof. Dr Jacques Devulder

Erschienen in: CNS Drugs | Ausgabe 10/2010

Einloggen, um Zugang zu erhalten

Abstract

Flupirtine is a centrally acting, non-opioid analgesic that is available in a number of European countries for the treatment of a variety of pain states. The therapeutic benefits seen with flupirtine relate to its unique pharmacological properties. Flupirtine displays indirect NDMA receptor antagonism via activation of potassium channels and is the first representative of a pharmacological class denoted the ‘selective neuronal potassium channel openers’. The generation of the M-current is facilitated by flupirtine via the opening of neuronal Kv7 potassium channels. The opening of these channels inhibits exaggerated neuronal action potential generation and controls neuronal excitability. Neuronal hyperexcitability is a physiological component of many pain states such as chronic pain, migraine and neurogenic pain.
Although large-scale clinical trials are lacking, the clinical trial database available to date from smaller-scale studies, together with extensive clinical experience, indicate that flupirtine effectively reduces chronic musculoskeletal pain, migraine and neuralgias, amongst other types of pain. In addition, flupirtine produces, at recommended clinical doses, muscle-relaxing effects in the presence of abnormally increased muscle tension. Its analgesic and muscle-relaxant properties were comparable to tramadol and chlormezanone, respectively, in two prospective trials in patients with lower back pain.
Cytoprotective, anti-apoptotic and antioxidant properties have also been associated with flupirtine use in a small number of studies to date. When provided as combination therapy with morphine, flupirtine increases the antinociceptive activity of morphine 4-fold. Flupirtine displays superior tolerability when compared with tramadol and pentazocine. The most common adverse effects associated with flupirtine use are drowsiness, dizziness, heartburn, dry mouth, fatigue and nausea.p ]With respect to its molecular structure, mechanism of action and adverse event profile, flupirtine is a unique drug. Flupirtine is an analgesic with many potential therapeutic benefits that may prove useful in the treatment of many disease states
Literatur
1.
Zurück zum Zitat Friedel HA, Fitton A. Flupirtine: a review of its pharmacological properties, and therapeutic efficacy in pain states. Drugs 1993; 45(4): 548–69PubMedCrossRef Friedel HA, Fitton A. Flupirtine: a review of its pharmacological properties, and therapeutic efficacy in pain states. Drugs 1993; 45(4): 548–69PubMedCrossRef
2.
Zurück zum Zitat Kornhuber J, Maler M, Wiltfang J, et al. Neuronal potassium channel opening with flupirtine. Fortschr Neurol Psychiatr 1999; 67(10): 466–75PubMedCrossRef Kornhuber J, Maler M, Wiltfang J, et al. Neuronal potassium channel opening with flupirtine. Fortschr Neurol Psychiatr 1999; 67(10): 466–75PubMedCrossRef
3.
Zurück zum Zitat Nickel B. The antinociceptive activity of flupirtine: a structurally new analgesic. Postgrad Med J 1987; 63 Suppl. 3: 19–28 Nickel B. The antinociceptive activity of flupirtine: a structurally new analgesic. Postgrad Med J 1987; 63 Suppl. 3: 19–28
4.
Zurück zum Zitat Szelenyi I, Nickel B, Borbe HO, et al. Mode of antinociceptive action of flupirtine in the rat. Br J Pharmacol 1989; 97(3): 835–42PubMedCrossRef Szelenyi I, Nickel B, Borbe HO, et al. Mode of antinociceptive action of flupirtine in the rat. Br J Pharmacol 1989; 97(3): 835–42PubMedCrossRef
5.
Zurück zum Zitat Darius H, Schror K. The action of flupirtine on prostaglandin formation and platelet aggregation in vitro. Arzneimittelforschung 1985; 35(1): 55–9PubMed Darius H, Schror K. The action of flupirtine on prostaglandin formation and platelet aggregation in vitro. Arzneimittelforschung 1985; 35(1): 55–9PubMed
6.
Zurück zum Zitat Kornhuber J, Bleich S, Wiltfang J, et al. Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels: rapid communication. J Neural Transm 1999; 106(9-10): 857–67PubMedCrossRef Kornhuber J, Bleich S, Wiltfang J, et al. Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels: rapid communication. J Neural Transm 1999; 106(9-10): 857–67PubMedCrossRef
7.
Zurück zum Zitat Jakob R, Krieglstein J. Influence of flupirtine on a G-protein coupled inwardly rectifying potassium current in hippo-campal neurones. Br J Pharmacol 1997; 122(7): 1333–8PubMedCrossRef Jakob R, Krieglstein J. Influence of flupirtine on a G-protein coupled inwardly rectifying potassium current in hippo-campal neurones. Br J Pharmacol 1997; 122(7): 1333–8PubMedCrossRef
8.
Zurück zum Zitat Methling K, Reszka P, Lalk M, et al. Investigation of the in vitro metabolism of the analgesic flupirtine. Drug Metab Dispos 2009 Mar; 37(3): 479–93PubMedCrossRef Methling K, Reszka P, Lalk M, et al. Investigation of the in vitro metabolism of the analgesic flupirtine. Drug Metab Dispos 2009 Mar; 37(3): 479–93PubMedCrossRef
9.
Zurück zum Zitat Miceli F, Soldovieri MV, Martire M, et al. Molecular pharmacology and therapeutic potential of neuronal Kv7-modulating drugs. Curr Opin Pharmacol 2008; 8(1): 65–74PubMedCrossRef Miceli F, Soldovieri MV, Martire M, et al. Molecular pharmacology and therapeutic potential of neuronal Kv7-modulating drugs. Curr Opin Pharmacol 2008; 8(1): 65–74PubMedCrossRef
10.
Zurück zum Zitat Blackburn-Munro G, Dalby-Brown W, Mirza NR, et al. Retigabine: chemical synthesis to clinical application. CNS Drug Rev 2005; 11(1): 1–20PubMedCrossRef Blackburn-Munro G, Dalby-Brown W, Mirza NR, et al. Retigabine: chemical synthesis to clinical application. CNS Drug Rev 2005; 11(1): 1–20PubMedCrossRef
11.
Zurück zum Zitat Szelenyi I, Nickel B. Putative site(s) and mechanism(s) of action of flupirtine, a novel analgesic compound. Postgrad Med J 1987; 63 Suppl. 3:57–60PubMedCrossRef Szelenyi I, Nickel B. Putative site(s) and mechanism(s) of action of flupirtine, a novel analgesic compound. Postgrad Med J 1987; 63 Suppl. 3:57–60PubMedCrossRef
12.
Zurück zum Zitat Abrams SM, Baker LR, Crome P, et al. Pharmacokinetics of flupirtine in elderly volunteers and in patients with moderate renal impairment. Postgrad Med J 1988; 64(751): 361–3PubMedCrossRef Abrams SM, Baker LR, Crome P, et al. Pharmacokinetics of flupirtine in elderly volunteers and in patients with moderate renal impairment. Postgrad Med J 1988; 64(751): 361–3PubMedCrossRef
13.
Zurück zum Zitat Hlavica P, Niebch G. Pharmacokinetics and biotransformation of the analgesic flupirtine in humans. Arzneimittelforschung 1985; 35(1): 67–74PubMed Hlavica P, Niebch G. Pharmacokinetics and biotransformation of the analgesic flupirtine in humans. Arzneimittelforschung 1985; 35(1): 67–74PubMed
14.
Zurück zum Zitat Hummel T, Friedmann T, Pauli E, et al. Dose-related analgesic effects of flupirtine. Br J Clin Pharmacol 1991; 32(1): 69–76PubMedCrossRef Hummel T, Friedmann T, Pauli E, et al. Dose-related analgesic effects of flupirtine. Br J Clin Pharmacol 1991; 32(1): 69–76PubMedCrossRef
15.
Zurück zum Zitat Schuster M, Schwarz M, Block F, et al. Flupirtine: a review of its neuroprotective and behavioral properties. CNS Drug Rev 1998; 4(2): 149–64CrossRef Schuster M, Schwarz M, Block F, et al. Flupirtine: a review of its neuroprotective and behavioral properties. CNS Drug Rev 1998; 4(2): 149–64CrossRef
16.
Zurück zum Zitat Metanor® [flupirtine maleate 100mg]: summary of product characteristics. Lisbon: Meda Pharmaceuticals, 2006 Metanor® [flupirtine maleate 100mg]: summary of product characteristics. Lisbon: Meda Pharmaceuticals, 2006
17.
Zurück zum Zitat Efiret® [flupirtine maleate 100mg capsule]: summary of product characteristics. Milan: Meda Pharmaceuticals, 2007 Efiret® [flupirtine maleate 100mg capsule]: summary of product characteristics. Milan: Meda Pharmaceuticals, 2007
18.
Zurück zum Zitat Mueller-Schwefe G. Flupirtine in acute and chronic pain associated with muscle tenseness: results of a postmarket surveillance study. Fortschr Med Orig 2003; 121(1): 11–8PubMed Mueller-Schwefe G. Flupirtine in acute and chronic pain associated with muscle tenseness: results of a postmarket surveillance study. Fortschr Med Orig 2003; 121(1): 11–8PubMed
19.
Zurück zum Zitat Luben V, Muller H, Lobisch M, et al. Treatment of tumor pain with flupirtine: results of a double-blind study versus tramadol. Fortschr Med 1994; 112(19): 282–6PubMed Luben V, Muller H, Lobisch M, et al. Treatment of tumor pain with flupirtine: results of a double-blind study versus tramadol. Fortschr Med 1994; 112(19): 282–6PubMed
20.
Zurück zum Zitat Li C, Ni J, Wang Z, et al. Analgesic efficacy and tolerability of flupirtine vs. tramadol in patients with subacute low back pain: a double-blind multicentre trial. Curr Med Res Opin 2008; 24(12): 3523–30 Li C, Ni J, Wang Z, et al. Analgesic efficacy and tolerability of flupirtine vs. tramadol in patients with subacute low back pain: a double-blind multicentre trial. Curr Med Res Opin 2008; 24(12): 3523–30
21.
Zurück zum Zitat Ringe JD, Miethe D, Pittrow D, et al. Analgesic efficacy of flupirtine in primary care of patients with osteoporosis related pain: a multivariate analysis. Arzneimittelforschung 2003; 53(7): 496–502PubMed Ringe JD, Miethe D, Pittrow D, et al. Analgesic efficacy of flupirtine in primary care of patients with osteoporosis related pain: a multivariate analysis. Arzneimittelforschung 2003; 53(7): 496–502PubMed
22.
Zurück zum Zitat Worz R, Bolten W, Heller B, et al. Flupirtine in comparison with chlormezanone in chronic musculoskeletal back pain: results of a multicenter randomized double-blind study. Fortschr Med 1996; 114(35-36): 500–4PubMed Worz R, Bolten W, Heller B, et al. Flupirtine in comparison with chlormezanone in chronic musculoskeletal back pain: results of a multicenter randomized double-blind study. Fortschr Med 1996; 114(35-36): 500–4PubMed
23.
Zurück zum Zitat Worz R. Flupirtine in chronic myofascial pain conditions. Fortschr Med 1991; 109(6): 158–60PubMed Worz R. Flupirtine in chronic myofascial pain conditions. Fortschr Med 1991; 109(6): 158–60PubMed
24.
Zurück zum Zitat Worz R, Lobisch M, Schwittmann B, et al. Effectiveness of flupirtine in chronic tension headache: results of a double-blind study versus placebo. Fortschr Med 1995; 113(32): 463–8PubMed Worz R, Lobisch M, Schwittmann B, et al. Effectiveness of flupirtine in chronic tension headache: results of a double-blind study versus placebo. Fortschr Med 1995; 113(32): 463–8PubMed
25.
Zurück zum Zitat Heusinger JH. Efficacy and tolerance of flupirtine and pentazocine in two multicentre trials. Postgrad Med J 1987; 63 Suppl. 3:71–9PubMed Heusinger JH. Efficacy and tolerance of flupirtine and pentazocine in two multicentre trials. Postgrad Med J 1987; 63 Suppl. 3:71–9PubMed
26.
Zurück zum Zitat Goodchild CS, Kolosov A, Tucker AP, et al. Combination therapy with flupirtine and opioid: studies in rat pain models. Pain Med 2008; 9(7): 928–38PubMedCrossRef Goodchild CS, Kolosov A, Tucker AP, et al. Combination therapy with flupirtine and opioid: studies in rat pain models. Pain Med 2008; 9(7): 928–38PubMedCrossRef
27.
Zurück zum Zitat Nickel B, Jakovlev V, Szelenyi I. The effect of flupirtine, various analgesics and muscle relaxants on skeletal muscle tone in the conscious rat. Arzneimittelforschung 1990; 40(8): 909–11PubMed Nickel B, Jakovlev V, Szelenyi I. The effect of flupirtine, various analgesics and muscle relaxants on skeletal muscle tone in the conscious rat. Arzneimittelforschung 1990; 40(8): 909–11PubMed
28.
Zurück zum Zitat Sitzer G. Einfacblindstudie mit Flupirtin gegen Acetyl-salicylsaure bei Patienten mit spinalem Wurzelreizsyndrom. Orthopadie/Traumatologie 1991; 6: 37–42 Sitzer G. Einfacblindstudie mit Flupirtin gegen Acetyl-salicylsaure bei Patienten mit spinalem Wurzelreizsyndrom. Orthopadie/Traumatologie 1991; 6: 37–42
29.
Zurück zum Zitat Mastronardi P, D’Onofrio M, Scanni E, et al. Analgesic activity of flupirtine maleate: a controlled double-blind study with diclofenac sodium in orthopaedics. J Int Med Res 1988; 16(5): 338–48PubMed Mastronardi P, D’Onofrio M, Scanni E, et al. Analgesic activity of flupirtine maleate: a controlled double-blind study with diclofenac sodium in orthopaedics. J Int Med Res 1988; 16(5): 338–48PubMed
30.
Zurück zum Zitat Marczyk LRS. Avaliacao comparativa do maleato de flupirtina versus diclofenaco potassico em afeccoes musculo-esqueleticas. Arq Bras Med 1992; 66(3): 269–75 Marczyk LRS. Avaliacao comparativa do maleato de flupirtina versus diclofenaco potassico em afeccoes musculo-esqueleticas. Arq Bras Med 1992; 66(3): 269–75
31.
Zurück zum Zitat Million R, Finlay BR, Whittington JR. Clinical trial of flupirtine maleate in patients with migraine. Curr Med Res Opin 1984; 9(3): 204–12PubMedCrossRef Million R, Finlay BR, Whittington JR. Clinical trial of flupirtine maleate in patients with migraine. Curr Med Res Opin 1984; 9(3): 204–12PubMedCrossRef
32.
Zurück zum Zitat Muller-Schwefe GH, Uberall MA. Analgesic and muscle tonus normalizing effect of flupirtine retard in chronic back pain: results of a standardized therapeutic evaluation applying objective methods for measuring pain pressure threshold, pain pressure tolerance and muscle tension. MMW Fortschr Med 2008; 149 Suppl. 4: 153–61 Muller-Schwefe GH, Uberall MA. Analgesic and muscle tonus normalizing effect of flupirtine retard in chronic back pain: results of a standardized therapeutic evaluation applying objective methods for measuring pain pressure threshold, pain pressure tolerance and muscle tension. MMW Fortschr Med 2008; 149 Suppl. 4: 153–61
33.
Zurück zum Zitat Scheef W. Analgesic efficacy and safety of oral flupirtine in the treatment of cancer pain. Postgrad Med J 1987; 63 Suppl. 3: 67–70 Scheef W. Analgesic efficacy and safety of oral flupirtine in the treatment of cancer pain. Postgrad Med J 1987; 63 Suppl. 3: 67–70
34.
Zurück zum Zitat Goodchild CS, Nelson J, Cooke I, et al. Combination therapy with flupirtine and opioid: open-label case series in the treatment of neuropathic pain associated with cancer. Pain Med 2008; 9(7): 939–49PubMedCrossRef Goodchild CS, Nelson J, Cooke I, et al. Combination therapy with flupirtine and opioid: open-label case series in the treatment of neuropathic pain associated with cancer. Pain Med 2008; 9(7): 939–49PubMedCrossRef
35.
Zurück zum Zitat Belgrade MJ. Following the clues to neuropathic pain: distribution and other leads reveal the cause and the treatment approach. Postgrad Med 1999; 106(6): 127–32, 135-40PubMed Belgrade MJ. Following the clues to neuropathic pain: distribution and other leads reveal the cause and the treatment approach. Postgrad Med 1999; 106(6): 127–32, 135-40PubMed
36.
Zurück zum Zitat Gassen M, Pergande G, Youdim MB. Antioxidant properties of the triaminopyridine, flupirtine. Biochem Pharmacol 1998; 56(10): 1323–9PubMedCrossRef Gassen M, Pergande G, Youdim MB. Antioxidant properties of the triaminopyridine, flupirtine. Biochem Pharmacol 1998; 56(10): 1323–9PubMedCrossRef
37.
Zurück zum Zitat Osborne NN, Cazevieille C, Pergande G, et al. Induction of apoptosis in cultured human retinal pigment epithelial cells is counteracted by flupirtine. Invest Ophthalmol Vis Sci 1997; 38(7): 1390–400PubMed Osborne NN, Cazevieille C, Pergande G, et al. Induction of apoptosis in cultured human retinal pigment epithelial cells is counteracted by flupirtine. Invest Ophthalmol Vis Sci 1997; 38(7): 1390–400PubMed
38.
Zurück zum Zitat Wood JP, Pergande G, Osborne NN. Prevention of glutathi-one depletion-induced apoptosis in cultured human RPE cells by flupirtine. Restor Neurol Neurosci 1998; 12(2-3): 119–25PubMed Wood JP, Pergande G, Osborne NN. Prevention of glutathi-one depletion-induced apoptosis in cultured human RPE cells by flupirtine. Restor Neurol Neurosci 1998; 12(2-3): 119–25PubMed
39.
Zurück zum Zitat Boscia F, Annunziato L, Taglialatela M. Retigabine and flupirtine exert neuroprotective actions in organotypic hippocampal cultures. Neuropharmacology 2006; 51(2): 283–94PubMedCrossRef Boscia F, Annunziato L, Taglialatela M. Retigabine and flupirtine exert neuroprotective actions in organotypic hippocampal cultures. Neuropharmacology 2006; 51(2): 283–94PubMedCrossRef
40.
Zurück zum Zitat Sattler MB, Williams SK, Neusch C, et al. Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis. Am J Pathol 2008; 173(5): 1496–507PubMedCrossRef Sattler MB, Williams SK, Neusch C, et al. Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis. Am J Pathol 2008; 173(5): 1496–507PubMedCrossRef
41.
Zurück zum Zitat Zimmer G, Balakirev M, Zwicker K, et al. Effect of the triaminopyridine flupirtine on calcium uptake, membrane potential and ATP synthesis in rat heart mitochondria. Br J Pharmacol 1998; 123(6): 1154–8PubMedCrossRef Zimmer G, Balakirev M, Zwicker K, et al. Effect of the triaminopyridine flupirtine on calcium uptake, membrane potential and ATP synthesis in rat heart mitochondria. Br J Pharmacol 1998; 123(6): 1154–8PubMedCrossRef
42.
Zurück zum Zitat Stoll AL. Fibromyalgia symptoms relieved by flupirtine: an open-label case series. Psychosomatics 2000; 41(4): 371–2PubMedCrossRef Stoll AL. Fibromyalgia symptoms relieved by flupirtine: an open-label case series. Psychosomatics 2000; 41(4): 371–2PubMedCrossRef
46.
Zurück zum Zitat Herrmann WM, Hiersemenzel R, Aigner M, et al. Long-term tolerance of flupirtine: open multicenter study over one year. Fortschr Med 1993; 111(15): 266–70PubMed Herrmann WM, Hiersemenzel R, Aigner M, et al. Long-term tolerance of flupirtine: open multicenter study over one year. Fortschr Med 1993; 111(15): 266–70PubMed
47.
Zurück zum Zitat Herrmann WM, Kern U, Aigner M. On the adverse reactions and efficacy of long-term treatment with flupirtine: preliminary results of an ongoing twelve-month study with 200 patients suffering from chronic pain states in arthrosis or arthritis. Postgrad Med J 1987; 63 Suppl. 3: 87–103PubMed Herrmann WM, Kern U, Aigner M. On the adverse reactions and efficacy of long-term treatment with flupirtine: preliminary results of an ongoing twelve-month study with 200 patients suffering from chronic pain states in arthrosis or arthritis. Postgrad Med J 1987; 63 Suppl. 3: 87–103PubMed
48.
Zurück zum Zitat McMahon FG, Arndt Jr WF, Newton JJ, et al. Clinical experience with flupirtine in the U.S. Postgrad Med J 1987; 63 Suppl. 3: 81–5PubMedCrossRef McMahon FG, Arndt Jr WF, Newton JJ, et al. Clinical experience with flupirtine in the U.S. Postgrad Med J 1987; 63 Suppl. 3: 81–5PubMedCrossRef
49.
Zurück zum Zitat Hirschowitz BI. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. Gastroenterologist 1994; 2(3): 207–23PubMed Hirschowitz BI. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. Gastroenterologist 1994; 2(3): 207–23PubMed
50.
Zurück zum Zitat Theifin G, Flipo RM, Schaeverbeke T, et al. Upper gastrointestinal symptoms in patients treated with NSAIDs: evaluation of physician-patient agreement and impact in the COMPLAINS study. 14th United European Gastro-enterology Week; 2006 Oct 21–25; Berlin Theifin G, Flipo RM, Schaeverbeke T, et al. Upper gastrointestinal symptoms in patients treated with NSAIDs: evaluation of physician-patient agreement and impact in the COMPLAINS study. 14th United European Gastro-enterology Week; 2006 Oct 21–25; Berlin
51.
Zurück zum Zitat Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001; 120(3): 594–606PubMedCrossRef Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001; 120(3): 594–606PubMedCrossRef
52.
Zurück zum Zitat Schug SA, Zech D, Grond S. Adverse effects of systemic opioid analgesics. Drug Saf 1992; 7(3): 200–13PubMedCrossRef Schug SA, Zech D, Grond S. Adverse effects of systemic opioid analgesics. Drug Saf 1992; 7(3): 200–13PubMedCrossRef
53.
Zurück zum Zitat Powell-Jackson P, Williams R. Use of flupirtine maleate as an analgesic in patients with liver disease. Br J Clin Pract 1985; 39(2): 63–6PubMed Powell-Jackson P, Williams R. Use of flupirtine maleate as an analgesic in patients with liver disease. Br J Clin Pract 1985; 39(2): 63–6PubMed
54.
Metadaten
Titel
Flupirtine in Pain Management
Pharmacological Properties and Clinical Use
verfasst von
Prof. Dr Jacques Devulder
Publikationsdatum
01.10.2010
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 10/2010
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/11536230-000000000-00000

Weitere Artikel der Ausgabe 10/2010

CNS Drugs 10/2010 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.